Atrial Flutter
Clinical Snapshot
Atrial flutter is a supraventricular tachyarrhythmia driven by a single, highly organized macro-reentrant electrical circuit — a fundamentally different mechanism from atrial fibrillation's chaotic, disorganized atrial activation. The most common form, typical (cavotricuspid-isthmus-dependent) flutter, circles a fixed anatomical loop in the right atrium at a very stable rate of roughly 250-350 times per minute (classically about 300/min), producing the characteristic "sawtooth" flutter-wave pattern on ECG. This chapter assumes familiarity with the Atrial Fibrillation chapter and deliberately does not repeat it: the Canadian Cardiovascular Society's 2020 guideline explicitly directs that atrial flutter be stratified and anticoagulated using the identical CHADS-65 algorithm as atrial fibrillation[1][2] — the full stroke-risk algorithm, DOAC dosing tables, and HAS-BLED bleeding-risk assessment live in that chapter and are not duplicated here. What genuinely differs, and is this chapter's focus, is the electrophysiology (a single organized circuit rather than chaotic multiple wavelets), the distinctive ECG signature, ventricular rate control that is often harder to achieve pharmacologically than in AF, and catheter ablation of the cavotricuspid isthmus being a first-line, curative option for typical flutter with a success rate exceeding 90% — a materially different treatment philosophy from AF, where ablation is an important option but is not uniformly positioned as first-line for every patient.[3]
Recognize the Condition
Typical presentation
Palpitations, fatigue, dyspnea, and reduced exercise tolerance are typical, similar to atrial fibrillation. Because typical flutter most often conducts to the ventricle at a fixed 2:1 ratio, the ventricular rate frequently sits at almost exactly 150 beats per minute — a strikingly regular narrow-complex tachycardia that can be mistaken for other regular SVTs (AVNRT/AVRT) or for sinus tachycardia. A persistently regular rate of approximately 150 bpm should raise suspicion for flutter with 2:1 block until proven otherwise. As with AF, a substantial share of flutter is identified incidentally or presents only with reduced exercise tolerance rather than palpitations, and symptom burden does not track with stroke risk.
Typical vs. atypical flutter — the electrophysiology that drives the treatment difference from AF
Typical (cavotricuspid-isthmus-dependent) flutter
The most common form of clinical flutter. The macro-reentrant circuit must cross the cavotricuspid isthmus — the tissue bridge between the tricuspid valve annulus and the inferior vena cava — making this narrow, well-defined strip of tissue a reliable and highly effective ablation target. The common counterclockwise variant produces negative sawtooth flutter waves in the inferior leads (II, III, aVF) and a positive deflection in V1; the less common clockwise ("reverse typical") variant produces the mirror-image pattern. Both are equally cavotricuspid-isthmus-dependent and equally curable by the same ablation procedure.[3]
Atypical flutter
Any macro-reentrant atrial circuit that does not depend on the cavotricuspid isthmus. Commonly related to atrial scar from prior cardiac surgery (a classic post-atriotomy circuit), prior catheter ablation — including a prior AF ablation — or extensive atrial fibrosis and structural heart disease. Flutter-wave morphology is variable and often lacks the classic sawtooth appearance. Characterizing the circuit typically requires 3D electroanatomic mapping, and ablation is more technically complex, with a lower success rate and higher recurrence than for typical flutter.[3]
Risk Factors
- Structural or valvular heart disease, prior myocardial infarction, and heart failure — shared with atrial fibrillation.
- Prior cardiac surgery involving an atriotomy — a leading, flutter-specific cause of atypical, scar-related circuits.
- Prior catheter ablation, including a prior AF ablation — a recognized cause of later scar/"gap"-related atypical flutter.
- Chronic obstructive pulmonary disease and other chronic pulmonary disease — a particularly strong, classically taught association with atrial flutter specifically.
- Hypertension, obesity, obstructive sleep apnea, diabetes mellitus, and chronic kidney disease — the same general cardiometabolic risk factors as atrial fibrillation.
- Hyperthyroidism.
- Digoxin toxicity — flutter with high-grade or unusually regular atrioventricular block is a classic toxic presentation.
- Congenital heart disease repaired in childhood with an atriotomy (for example, after a Fontan procedure) — a lifelong flutter risk from the surgical scar.
- Advancing age and male sex.
- Coexistence with atrial fibrillation — many patients with flutter also have, or go on to develop, AF from the same diseased atrial substrate; the two arrhythmias are closely linked, not separate diseases with independent risk profiles.
Red Flags & Refer
Escalate or refer urgently for any of the following:
- Hemodynamic instability, particularly with a very rapid, near-1:1 ventricular response (rates approaching 250-300 bpm) — needs emergency synchronized electrical cardioversion, not outpatient rate-control titration.
- Signs or symptoms of acute stroke or TIA — activate the emergency stroke pathway immediately, exactly as for atrial fibrillation.
- Flutter with ventricular pre-excitation (Wolff-Parkinson-White) — the same principle as pre-excited atrial fibrillation applies: do not give an AV-nodal blocking agent (beta-blocker, non-dihydropyridine calcium channel blocker, digoxin, or adenosine), since these can accelerate conduction down the accessory pathway; manage with procainamide or electrical cardioversion and obtain expert/electrophysiology input.
- A sudden increase in ventricular rate after starting flecainide or propafenone without a concurrent AV-nodal-blocking agent — suspect the drug has slowed the flutter rate enough to permit dangerous 1:1 AV conduction; stop the drug and treat the rapid ventricular response as an emergency.
- New or worsening flutter with high-grade or unusually regular AV block in a patient taking digoxin — consider digoxin toxicity and check a level before simply escalating AV-nodal-blocking therapy further.
- Ventricular rate that remains uncontrolled despite optimized first-line rate-control therapy — refer promptly for catheter ablation assessment; for typical flutter, ablation's high success rate makes this a preferred next step sooner than the equivalent point in AF management.
Assessment & Diagnosis
Confirming the diagnosis
- 12-lead ECG showing regular atrial activity at approximately 250-350 beats per minute (classically about 300/min) with no isoelectric baseline between flutter waves — the "sawtooth" pattern. Typical counterclockwise flutter shows negative sawtooth waves in the inferior leads (II, III, aVF) and a positive deflection in V1; the clockwise variant shows the mirror image. Atypical flutter often lacks this classic morphology.[3]
- The ventricular rate is a fixed fraction of the atrial rate — most often 2:1 (giving a rate near 150 bpm), less often 3:1 or 4:1 — though the conduction ratio can vary (including a Wenckebach-type pattern), producing an irregular ventricular rate that can superficially resemble atrial fibrillation. Look specifically for the organized, regular flutter-wave baseline to distinguish the two.
- When flutter waves are not clearly visible — for example, buried in a fast baseline — a vagal maneuver or IV adenosine given during continuous ECG recording can transiently increase AV block and unmask the flutter waves without terminating the rhythm; this is diagnostically useful even though it is not curative.[3]
- Echocardiography to assess left atrial size, left ventricular ejection fraction, and structural or valvular heart disease — the same rationale as atrial fibrillation, and LVEF still governs which rate-control and rhythm-control drugs are appropriate.
- TSH, to identify hyperthyroidism as a reversible contributor.
- A digoxin level if the patient is taking digoxin and presents with new or worsening high-grade AV block.
- Electrolytes and renal function, both as a general baseline and because they are required inputs for anticoagulant dosing.
Stroke-risk and bleeding-risk assessment — identical to atrial fibrillation
Apply the CHADS-65 algorithm exactly as described in the Atrial Fibrillation chapter: age 65 or older, or any CHADS2 risk factor at any age, warrants anticoagulation, with a DOAC preferred over warfarin for nonvalvular disease.[1][2] Bleeding risk is assessed with HAS-BLED, also exactly as in that chapter. Neither algorithm is repeated here — atrial flutter is not treated as a lower-risk arrhythmia for stroke-prevention purposes, so the full tables, DOAC renal/age/weight dosing, and bleeding-risk stratification in the Atrial Fibrillation chapter apply without modification.
Treatment Targets
- Prevent stroke and systemic embolism, using the identical priority and CHADS-65-based decision as atrial fibrillation.
- Achieve adequate ventricular rate control — recognizing this is frequently harder to titrate reliably than in atrial fibrillation.
- Restore and maintain sinus rhythm, actively considering catheter ablation of the cavotricuspid isthmus as a first-line strategy for typical flutter rather than only after drug therapy has failed.
- Identify and correct reversible contributors: thyrotoxicosis, digoxin toxicity, an uncontrolled pulmonary exacerbation, or a recent cardiac surgery-related scar circuit.
- Recognize that flutter and AF frequently coexist or that one follows the other from the same diseased atrial substrate, and monitor accordingly even after apparently successful flutter treatment.
Choose Initial Treatment
Every patient with confirmed atrial flutter apply the CHADS-65 algorithm exactly as for atrial fibrillation — age 65 or older, or any CHADS2 risk factor at any age, warrants anticoagulation, with a DOAC preferred over warfarin for nonvalvular disease.[1][2] See the Atrial Fibrillation chapter for the complete algorithm, DOAC renal/age/weight dosing tables, and HAS-BLED bleeding-risk assessment.
Drug selection mirrors atrial fibrillation — LVEF ≤ 40% an evidence-based beta-blocker; LVEF > 40% a beta-blocker or a non-dihydropyridine calcium channel blocker (diltiazem or verapamil), with digoxin added when first-line therapy is insufficient. What differs is how hard the target is to hit: flutter is driven by a single, organized circuit firing at a fixed rate into the AV node, which typically responds in stepwise integer ratios (2:1, 3:1, 4:1) rather than the more continuously variable, decrementally conducted response it has to AF's chaotic activity. Conduction can shift abruptly between ratios — including transiently to 1:1 — with exertion, illness, or sympathetic activation, so a steady, well-controlled ventricular rate is often genuinely harder to achieve, and higher or combination doses are frequently needed compared with AF.[3]
Typical (cavotricuspid-isthmus-dependent) flutter catheter ablation of the cavotricuspid isthmus should be discussed as a first-line, curative option at the first specialist visit — not only after drug therapy has failed — given a success rate exceeding 90% (up to about 95% in some series) and a low complication rate.[3][4][5] This is a materially different treatment philosophy from atrial fibrillation, where ablation is an important option but is not uniformly positioned as the first-line strategy for every patient.
Atypical flutter ablation is still an option and is often the most effective long-term strategy, but the procedure is substantially more complex — usually requiring 3D electroanatomic mapping of a non-cavotricuspid-isthmus circuit — with a lower success rate and more frequent recurrence than typical flutter.
The 2019 ESC supraventricular tachycardia guideline goes further still: it no longer recommends chronic antiarrhythmic drug therapy (dofetilide, sotalol, flecainide, propafenone, procainamide, quinidine, or disopyramide) for long-term management of atrial flutter at all, reflecting a stronger preference for curative ablation over indefinite drug therapy than exists for AF.[5]
Never use flecainide or propafenone for flutter without a concurrent AV-nodal-blocking agent — as in AF, slowing the flutter rate with a Class IC drug can paradoxically permit 1:1 AV conduction and a dangerous, rapid ventricular response.
Electrical (DC) cardioversion is highly effective for flutter given its organized rhythm, often successful at a lower energy than is typically needed for AF. Overdrive atrial pacing — pacing faster than the flutter rate via an existing pacemaker/ICD atrial lead, or via temporary epicardial wires after cardiac surgery — can terminate typical flutter without a shock, an option that does not exist for AF's disorganized activation. For pharmacologic cardioversion, ibutilide has meaningfully higher conversion rates in flutter than in AF and is generally preferred over other agents for this indication — see Pharmacologic Treatment Options.[6] Pre- and post-cardioversion anticoagulation requirements are identical to AF and are not repeated here.
Non-Pharmacologic Treatment
- Catheter ablation of the cavotricuspid isthmus — a first-line, curative option for typical flutter, with success exceeding 90%.[3]
- Ablation of atypical flutter — more complex, requiring 3D electroanatomic mapping of the specific non-cavotricuspid-isthmus circuit; lower success rate and more frequent recurrence than typical flutter, but still worthwhile for symptomatic or drug-refractory disease.
- Electrical cardioversion — highly effective given flutter's organized rhythm, often at a lower energy than typically required for AF; the same pre- and post-cardioversion anticoagulation requirements as AF apply.
- Overdrive atrial or transesophageal pacing — a distinctive option for organized flutter, able to terminate typical flutter without a shock when an existing pacemaker/ICD atrial lead or temporary epicardial wires are available.
- AV-node ablation with permanent pacemaker implantation — a last-resort rate-control option when pharmacologic rate control fails, as in AF, though reached less often for typical flutter given how effective and safe cavotricuspid isthmus ablation is.
- Treat reversible contributors directly: thyrotoxicosis, an uncontrolled pulmonary disease exacerbation, or digoxin toxicity.
- Left atrial appendage occlusion — the same alternative stroke-prevention strategy as AF, for patients at high stroke risk with a genuine contraindication to long-term oral anticoagulation; not repeated here beyond this cross-reference.
Special Populations
Pregnancy
Rate control with a beta-blocker (e.g., metoprolol) is preferred, as in AF. Electrical cardioversion is considered safe at any stage of pregnancy, given the low energy reaching the fetus, and is often favoured over pharmacologic cardioversion; data on ibutilide and procainamide in pregnancy are limited, so reserve them for situations where cardioversion cannot be delayed. Anticoagulation follows the identical approach to AF in pregnancy (low-molecular-weight or unfractionated heparin preferred over DOACs and warfarin) — see the Atrial Fibrillation chapter.
Breastfeeding
Beta-blockers used for rate control are generally considered compatible with breastfeeding, as in AF; anticoagulant selection in lactation follows the same approach described in that chapter.
Chronic obstructive pulmonary disease and other pulmonary disease
Flutter has a particularly strong, classic association with COPD and other chronic pulmonary disease. Avoid nonselective beta-blockers given the bronchospasm risk; a cardioselective agent (metoprolol, bisoprolol) or a non-dihydropyridine calcium channel blocker is preferred. Treating the underlying pulmonary exacerbation often substantially eases rate control, and sometimes resolves the flutter altogether.
Recent cardiac surgery
Flutter — often atypical, scar-related to the surgical atriotomy — is common in the early postoperative period and is frequently self-limited. When temporary epicardial pacing wires are present, overdrive atrial pacing can terminate it without cardioversion or additional drug therapy.
Digoxin toxicity
New or worsening flutter with high-grade or unusually regular AV block in a patient taking digoxin should prompt a digoxin level and toxicity workup — not simply the addition of more AV-nodal-blocking therapy.
Patients with a prior AF or flutter ablation
New flutter after a prior ablation — including a prior AF ablation — is a recognized presentation of scar/"gap"-related atypical flutter; refer back to electrophysiology rather than assuming the original procedure has simply failed outright.
Renal impairment and elderly patients
Ibutilide and procainamide carry a higher proarrhythmic/torsades risk in elderly patients and in significant structural heart disease — use with caution and continuous ECG monitoring. Renal-function-based anticoagulant dosing principles are identical to AF and are not repeated here.
Monitoring & Follow-Up
- Renal function and anticoagulation monitoring follow the identical cadence as atrial fibrillation — not repeated here; see that chapter.
- Reassess ventricular rate control and symptom burden at routine follow-up, and escalate toward ablation referral rather than simply re-reassuring if targets are not being met.
- After cavotricuspid isthmus ablation, confirm the treating electrophysiologist has documented procedural success (bidirectional isthmus block), and monitor for symptomatic recurrence.
- Actively monitor for the development of atrial fibrillation even after a technically successful flutter ablation. Because the same diseased atrial substrate that produced the flutter often also predisposes to AF, a substantial proportion of patients develop AF after CTI ablation. Continue anticoagulation based on the ongoing CHADS-65 result and current risk factors — not on the flutter having been "cured."
- Continuous ECG/QTc monitoring during and for several hours after ibutilide or procainamide administration, given their torsades de pointes risk.
- Periodic TSH follow-up if hyperthyroidism was identified as a contributing, reversible factor.
Common Errors to Avoid
- Treating flutter's stroke risk as lower than AF's, or withholding anticoagulation because it is "just flutter" — the CHADS-65 algorithm and its recommendation are identical.
- Using flecainide or propafenone for flutter without a concurrent AV-nodal-blocking agent — this risks a rate-slowed 1:1 conduction and a dangerous, rapid ventricular response.
- Missing flutter with 2:1 block because the ventricular rate looks like an unremarkable, perfectly regular tachycardia near 150 bpm.
- Escalating rate-control drug doses indefinitely rather than referring for cavotricuspid isthmus ablation once first-line therapy proves inadequate for typical flutter.
- Treating a technically successful cavotricuspid isthmus ablation as having eliminated all future arrhythmia or stroke risk — atrial fibrillation frequently develops afterward from the same diseased atrial substrate.
- Missing digoxin toxicity as a cause of new-onset flutter with high-grade AV block, and responding by adding more AV-nodal-blocking therapy instead of checking a level and holding the drug.
- Giving ibutilide without first correcting potassium and magnesium, or without the required continuous ECG monitoring for at least 4 hours afterward, given its real torsades de pointes risk.
- Assuming atypical flutter will respond to cavotricuspid isthmus ablation the same way typical flutter does — it requires a different, more complex mapping-guided procedure and carries a lower success rate.
Clinical Decision Algorithm
Drug Tables
How to use this table: Anticoagulants (DOACs and warfarin) for stroke prevention are identical to atrial fibrillation and are covered in full in the Atrial Fibrillation chapter's drug tables — they are not repeated here. This table covers only the drug classes genuinely specific to, or genuinely different in, atrial flutter: rate control and pharmacologic cardioversion. Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.
Rate control — beta-blockers
Preferred class for rate control at any left ventricular ejection fraction. Flutter's single, fixed-rate reentrant circuit is frequently harder to control than AF's more chaotic conduction, so higher or combination dosing is common.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Metoprolol | Tartrate: 25-100 mg PO BID. Succinate (extended-release): 50-200 mg PO once daily. IV (acute rate control): 2.5-5 mg IV over 2 minutes, may repeat every 5 minutes to 3 doses. | Bradycardia, hypotension, fatigue, bronchospasm | Additive bradycardia with diltiazem, verapamil, or digoxin. | If a resting rate under 100 bpm is not reached on a reasonable dose, add a second rate-control agent or refer for ablation rather than escalating monotherapy indefinitely. |
| Bisoprolol | 2.5-10 mg PO once daily. | Bradycardia, hypotension, fatigue | Additive bradycardia with diltiazem, verapamil, or digoxin. | Evidence-based option specifically in LVEF ≤40%, as in AF. |
Rate control — non-dihydropyridine calcium channel blockers
Use only if LVEF is greater than 40% — negative inotropy can worsen heart failure with reduced ejection fraction.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Diltiazem | Extended-release: 120-360 mg PO once daily, started low and titrated. IV (acute): 0.25 mg/kg bolus over 2 minutes, then infusion. | Hypotension, bradycardia, peripheral edema, constipation, worsening heart failure | Additive bradycardia with beta-blockers or digoxin; CYP3A4 substrate/inhibitor. | Avoid in LVEF ≤40%/HFrEF. Flutter often needs the higher end of the dose range or combination with a beta-blocker. |
| Verapamil | Sustained-release: 120-360 mg PO once daily. | Hypotension, bradycardia, constipation, worsening heart failure | Additive bradycardia with beta-blockers or digoxin; P-gp/CYP3A4 interactions (raises dabigatran levels — avoid concurrent initiation). | Avoid in LVEF ≤40%/HFrEF. |
Rate control — cardiac glycoside
Add-on when first-line therapy is insufficient. Notably less useful as monotherapy in flutter than in AF, since it does not blunt the fixed, rapid atrial rate driving conduction.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Digoxin | Loading (if needed): 0.25 mg PO/IV every 6 hours, up to 3 doses in 24 hours (maximum 1.5 mg/24h). Maintenance: 0.125-0.25 mg PO once daily; reduce in renal impairment, the elderly, or low body weight. | Nausea, visual disturbance, arrhythmia — narrow therapeutic index | Amiodarone and verapamil raise digoxin levels significantly (reduce digoxin dose); hypokalemia and hypomagnesemia increase toxicity risk. | Ineffective as flutter monotherapy in an active patient. New or worsening flutter with high-grade AV block in a digoxin-treated patient should prompt a level, not a dose increase. |
Pharmacologic cardioversion — Class III antiarrhythmic
Ibutilide is generally preferred over other pharmacologic cardioversion agents specifically because its efficacy in flutter meaningfully exceeds its efficacy in AF — a genuine point of difference from atrial fibrillation management.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ibutilide | 1 mg IV infused over 10 minutes (0.01 mg/kg if body weight is under 60 kg); may repeat one additional 1 mg dose after waiting 10 minutes if flutter persists. | QT prolongation, torsades de pointes (up to about 4% with monotherapy), monomorphic ventricular tachycardia | Avoid with other QT-prolonging drugs. Combining with a Class IC agent (flecainide/propafenone) may lower torsades risk but is not routine practice. | Reported conversion rates are meaningfully higher for atrial flutter than for atrial fibrillation (one review: 87% vs. 77% in recent-onset cases). Correct potassium and magnesium before infusion; monitor continuously by ECG during and for at least 4 hours after infusion given the torsades risk.[6] |
Pharmacologic cardioversion — Class Ia antiarrhythmic
An alternative to ibutilide, and the preferred agent specifically when pre-excitation (Wolff-Parkinson-White) is suspected, since it slows accessory-pathway conduction directly.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Procainamide | 100 mg IV every 5 minutes (rate not exceeding 50 mg/minute) until the arrhythmia is suppressed or a total of 1 g has been given, then a maintenance infusion of 2-6 mg/minute. | Hypotension (can be precipitous with IV use), QRS widening, torsades de pointes | Additive QT prolongation with other QT-prolonging drugs; amiodarone reduces its clearance. | Chosen specifically when AV-nodal-blocking agents must be avoided because pre-excitation is suspected — the same principle as pre-excited atrial fibrillation. |
Rhythm control — special situation
Reserved, as in AF, for reduced ejection fraction or refractory disease given its toxicity burden.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Amiodarone | Loading: 400-600 mg PO daily (divided) for 2-4 weeks. Maintenance: 100-200 mg PO once daily. IV loading is also used acutely in a monitored setting. | Thyroid dysfunction, pulmonary fibrosis, hepatotoxicity, corneal microdeposits, photosensitivity, bradycardia | Potent CYP3A4/2C9/P-gp inhibitor — significantly increases warfarin, digoxin, and dabigatran levels. | As in AF, the only rhythm-control agent considered safe in LVEF ≤40%/HFrEF. |
References
- The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation — Canadian Journal of Cardiology, Canadian Cardiovascular Society/Canadian Heart Rhythm Society (Andrade JG, Aguilar M, Atzema C, et al.). Can J Cardiol 2020;36(12):1847-1948
- The 2020 CCS atrial fibrillation guidelines for pharmacists: Top 10 takeaways — Canadian Pharmacists Journal (LeBlanc K, MacGillivray J, Carroccia A, Macle L, Andrade JG). Can Pharm J 2022;155(2):73-82
- Atrial Flutter — StatPearls, NCBI Bookshelf (Rodriguez Ziccardi M, Goyal A, Maani CV). StatPearls Publishing, updated December 8, 2022
- 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia — Circulation, American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society (Page RL, Joglar JA, Caldwell MA, et al.). Circulation 2016;133(14):e506-e574
- 2019 ESC Guidelines for the management of patients with supraventricular tachycardia — European Heart Journal, European Society of Cardiology (Brugada J, Katritsis DG, Arbelo E, et al.). Eur Heart J 2020;41(5):655-720
- Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation — The Journal of the American Board of Family Medicine (Nair M, George LK, Koshy SKG). J Am Board Fam Med 2011;24(1):86-92
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.